Showing results (681-690 of 2,410) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|May 3, 2016
The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in TaiwanHui-Chu Lang, Hsiao-Wei Chen, Tzeon-Jye Chiou, et al.Journal of Medical Economics|May 6, 2016
Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in CanadaManjusha Hurry, Zheng-Yi Zhou, Jie Zhang, et al.Journal of Medical Economics|May 6, 2016
Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in SwedenSara Olofsson, Hanna Norrlid, Ulf PerssonJournal of Medical Economics|November 28, 2015
The impact of economic factors on treatment results for tumor inpatients in the under-developed Western region of ChinaJun-Xiu Xu, Jian-Min Gao, Rong Peng, et al.Journal of Medical Economics|December 2, 2015
Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis CJoyce LaMori, Neeta Tandon, François Laliberté, et al.Journal of Medical Economics|October 11, 2017
The value of self-medication: summary of existing evidenceJoshua Noone, Christopher M BlanchetteJournal of Medical Economics|January 28, 2020
Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysisJashin J Wu, Jes B Hansen, Dharm S Patel, et al.Journal of Medical Economics|September 28, 2019
Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from ThailandPochamana Phisalprapa, Siripen Supakankunti, Nathorn ChaiyakunaprukJournal of Medical Economics|February 2, 2017
The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular eventsWenjie Zhang, Yi Han, John G Fort, et al.Journal of Medical Economics|January 17, 2017
The 21st Century Cures Act: pharmacoeconomic boon or bane?Roger Lee MendozaPageof 241